[
    [
        {
            "time": "2023-10-18",
            "original_text": "Pfizer Presents Overall Survival Data From PALOMA-3 Trial of IBRANCEÂ® (palbociclib) in Patients With HR+, HER2- Metastatic Breast Cancer",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Overall Survival",
                    "PALOMA-3",
                    "IBRANCE",
                    "palbociclib",
                    "HR+",
                    "HER2-",
                    "Metastatic Breast Cancer"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]